Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy

NCT ID NCT06222489

Recruiting now Diagnosis Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether a radiolabelled version of the drug patritumab deruxtecan (HER3-DXd) can be used as a PET imaging tracer to visualize HER3 protein throughout the body in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the best imaging dose and see if the tracer can accurately show HER3 levels in tumors, which might help predict who could benefit from HER3-targeted treatment. Participants will receive the tracer and undergo PET/CT scans at several time points during their first treatment course.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radiolabelled form of the drug patritumab deruxtecan (HER3-DXd) used as a PET imaging tracer
What this could lead to: If successful, this imaging approach could help doctors see where HER3 is present in the body, potentially identifying which patients are most likely to benefit from HER3-targeted therapy.
What could go wrong: This is a small, early-phase imaging study, so it may not lead to a proven clinical tool. The tracer involves radiation exposure, and the optimal imaging dose is still being determined.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL SQUAMOUS LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL SQUAMOUS LUNG CANCER EGFR GENE MUTATION NON-SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

Antoni van Leeuwenhoek
RECRUITING

Amsterdam, North Holland, 1066CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.